98%
921
2 minutes
20
Background: The Oxidative Balance Score (OBS) is a new measure for assessing systemic oxidative stress, where higher scores indicate increased exposure to antioxidants. However, the relationship between the OBS and mortality in individuals with hypertension remains unclear.
Methods: This study evaluated 8151 hypertensive individuals from the National Health and Nutrition Examination Survey (NHANES) (2001-2018), utilizing data from the National Death Index, tracked through December 31, 2019. The association between OBS and mortality (cardiovascular and all-cause) was examined using multivariable Cox regression models.
Results: During a median follow-up of 9.7 years, which included 1692 deaths (461 of which were cardiovascular), multivariable Cox regression showed the highest quartile of OBS had significantly lower rates of all-cause mortality (hazard ratio (HR) 0.761, 95% CI: 0.635-0.912) and cardiovascular mortality (HR 0.553, 95% CI: 0.388-0.788) compared to those in the lowest quartile. An increase of one unit in the OBS was associated with a 1.9% reduction in all-cause mortality risk and a 3.7% reduction in cardiovascular mortality risk. This relationship remained consistent across various subgroup analyses, and spline regression supported a linear inverse trend.
Conclusions: For adults with hypertension, an elevated OBS is independently associated with a lower risk of mortality both from all-cause and cardiovascular diseases, suggesting that higher antioxidant levels may be protective.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415749 | PMC |
http://dx.doi.org/10.31083/RCM37415 | DOI Listing |
JAMA Cardiol
September 2025
Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, New York.
Importance: Transthyretin cardiac amyloidosis (ATTR-CA) is an underdiagnosed but treatable cause of heart failure (HF) in older individuals that occurs in the context of normal wild-type (ATTRwt-CA) or an abnormal inherited (ATTRv-CA) TTR gene variant. While the most common inherited TTR variant, V142I, occurs in 3% to 4% of self-identified Black Americans and is associated with excess morbidity and mortality, the prevalence of ATTR-CA in this at-risk population is unknown.
Objective: To define the prevalence of ATTR-CA and proportions attributable to ATTRwt-CA or ATTRv-CA among older Black and Caribbean Hispanic individuals with HF.
Hormones (Athens)
September 2025
Division of Endocrinology, Baltimore VA Medical Center, Baltimore, MD, USA.
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a fairly new class of agents for diabetes that have demonstrated significant benefits in glycemic control and cardiovascular outcomes with outpatient use. The aim of this review is to provide an overview of the effect of SGLT2i use on glycemic control and clinical outcomes in the hospital setting.An electronic search of PubMed was conducted to analyze publications that assessed the inpatient use of SGLT2i and included patients with diabetes.
View Article and Find Full Text PDFCurr Atheroscler Rep
September 2025
Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Purpose Of Review: Despite major advances in the treatment and prevention of atherosclerotic cardiovascular disease (ASCVD), a substantial burden of residual risk remains Obesity has been redefined as a primary and independent drivers of cardiovascular morbidity and mortality warranting focused attention.
Recent Findings: Obesity is now recognized as a chronic disease and a central contributor to residual cardiovascular risk through mechanisms including systemic inflammation, insulin resistance, dyslipidemia, and endothelial dysfunction. This review addresses the limitations of conventional obesity management and highlights emerging pharmacological therapies targeting the underlying adiposopathy.
J Cardiovasc Transl Res
September 2025
School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, 519000, China.
Atherosclerosis remains a leading cause of cardiovascular disease and mortality worldwide, despite advancements in statin therapies. Here, we aimed to identify potential anti-atherosclerosis drugs by an integrated approach combining network medicine-based prediction with empirical validation. Among the top drugs predicted by the preferred algorithm, mesalazine─a drug traditionally used to treat inflammatory bowel disease, was selected for in vivo validation in ApoE mouse model of atherosclerosis.
View Article and Find Full Text PDFEur Heart J
September 2025
Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Venusberg-Campus 1, Bonn 53127, Germany.
Background And Aims: Fulminant myocarditis (FM) is a complex clinical syndrome characterized by acute myocardial inflammation and cardiogenic shock. Evidence on long-term outcomes, mortality risk factors, and targeted treatment options remains limited.
Methods: This retrospective analysis included consecutive adult patients admitted for FM between January 2012 and November 2022 at 26 European tertiary centres.